Oral Cancer News – Page 185 – The Oral Cancer Foundation News Archive

HPV- Related Head and Neck Cancers Increase while Non-HPV Related Head and Neck Cancers Decrease in Canada

Source: SAGE Journals Online Abstract Objective: 1) Learn how the incidence of HPV-related and non-HPV-related Head and Neck Cancers (HNC) in Canada has changed in the time period 1992 to 2008. 2) Learn how the age at diagnosis and overall survival for these cancers in Canada has changed over that period. Method: We used Canadian Cancer Registry Data (1992-2008), categorizing HNCs into 3 groups: (High (HHPV), ie, oropharynx; Moderate (MHPV), ie, oral cavity; and Low (LHPV), ie, larynx); based on the probability that HPV causes the cancer. We calculated age-adjusted incidence, median age at diagnosis, and survival for each category. Results: HHPV cancers increased in incidence at an average annual rate (AAR) of 1.02% (P = .010); MHPV and LHPV cancers decreased at an AAR of 2.38% (P = .000) and 3.67% (P = .000) respectively. The median age at diagnosis for HHPV cancers decreased by an average of 0.23 years/year (P = .000). There was no change for MHPV and an increase for LHPV of 0.10 years/year (P = .008). Survival for patients with HHPV cancers increased by 2.1%/year (P = .000), compared with an increase of 1.6% per year for MHPV (P = .003) and a marginal increase in LHPV of 0.6% per year (P = .002). Conclusion: The prevalence of HPV-related head and neck cancers in Canada is increasing, while the prevalence of non-HPV–related head and neck cancers is decreasing. This has been accompanied by a decrease in both age at diagnosis and mortality in HPV related [...]

Oral Cancer Foundation News Team - A2011-09-05T09:01:50-07:00September, 2011|Oral Cancer News|

A step toward a saliva test for cancer

Source: www.sciencedaily.com Author: staff A new saliva test can measure the amount of potential carcinogens stuck to a person's DNA -- interfering with the action of genes involved in health and disease -- and could lead to a commercial test to help determine risks for cancer and other diseases, scientists reported in Denver during the 242nd National Meeting & Exposition of the American Chemical Society (ACS). "The test measures the amount of damaged DNA in a person's body," said Professor Hauh-Jyun Candy Chen, Ph.D., who led the research team. "This is very important because such damaged DNA -- we call this 'DNA adducts' -- is a biomarker that may help doctors diagnose diseases, monitor how effective a treatment is and also recommend things high-risk patients can do to reduce the chances of actually getting a disease," said Chen. The research team is at National Chung Cheng University (NCCU) in Taiwan. "We tried urine and blood and found these adducts. Then we turned our attention to saliva. It's much more convenient to collect a sample of saliva." A DNA adduct forms when a potentially cancer-causing substance is chemically attached to a strand of DNA, which makes up genes. People come into contact with such substances in the environment, certain workplaces and through everyday activities. Cigarette smoke, for instance, contains at least 20 known cancer-causing substances. When such a substance binds to DNA, it changes the DNA so that genes may not work normally. Our body has a built-in repair system that [...]

Oral Cancer Foundation News Team - A2011-09-02T19:27:30-07:00September, 2011|Oral Cancer News|

Trans-oral robotic surgery has all the right stuff to remove head & neck cancers

Source: inventorspot.com Author: T Goodman Historically, surgical removal or oral and throat cancers have not allowed patients to go back to living their normal daily lives. Oral cancer removals caused severe pain, particularly ugly scarring, and an inability to eat, speak, or swallow normally. Even breathing problems might result. But now along comes TORS, the robot with the right stuff. Just over a dozen hospitals in the U.S. currently have the TORS, which stands for Trans-Oral Robotic Surgery. The system uses the da Vinci Surgical System, which has developed since the mid 90's to arguably be the most successful robotic surgery system in the world. It employs tiny robotic surgical instruments, operated from a command station by the appropriately trained human surgeon who maneuvers the robot's 'arms' and instruments. As with other da Vinci procedures, TORS has the benefits of being less invasive, with fewer complications and shorter hospital stays. There is less blood loss, little scarring, and fewer temporary and permanent side effects, such as loss of speech or swallowing ability. Generally, there is no need to begin cancer therapy with radiation, which would increase the discomfort and recovery time. Tamer A. Ghanem, M.D., Ph.D., director of Head and Neck Oncology and Reconstructive Surgery Division in the Department of OtolaryngologyHead & Neck Surgery at Henry Ford Hospital in Detroit, says that with TORS, "Surgeons operate with greater precision and control using the TORS approach, minimizing the pain, and reducing the risk of possible [...]

Oral Cancer Foundation News Team - A2011-09-02T19:22:47-07:00September, 2011|Oral Cancer News|

Scientific literature supports safety of essential oil mouthrinses

Source: www.dentistryiq.com Author: Christine Charles, RDH Antimicrobial mouthrinses provide anti-plaque and anti-gingivitis benefits beyond brushing and flossing alone. An antimicrobial mouthrinse where the active ingredient is the fixed combination of four essential oils (EO), thymol, menthol, eucalyptol and methyl salicylate in a hydroalcohol solution (pharmaceutical grade ethanol functions as a solvent, a vehicle for the active ingredients and as a preservative in a mouthrinse), has been proven clinically effective and safe in over 50 clinical trials, including 6-month trials with plaque reductions up to 70.0%(1) and gingivitis reductions up to 36%(1,2) compared with negative control. Sharma, et al, showed the clinically significant incremental benefit of including an EO antimicrobial mouthrinse in a daily mechanical oral regimen of brushing and flossing.(3) Mechanical oral hygiene techniques generally focus on the teeth, but teeth comprise only about 25% of the surface area of the mouth. Bacteria are also prevalent on the other 75% of the mouth’s surface area, in bacterial reservoirs on the tongue, cheek, palate and oral mucosa.(4) A mouthrinse can reach the rest of the mouth, where a toothbrush and floss cannot. EO works by killing planktonic and biofilm-associated bacteria and a broad spectrum of bacteria and yeasts associated with halitosis, gingivitis and periodontitis by: (1) disrupting bacterial cell membranes and cell walls, (2) inhibiting bacterial growth and development, (3) inhibiting glucosyltransferase (gtf) enzymes, reducing extracellular polysaccharide (EPS) formation, and (4) reducing plaque endotoxin levels.(5) The scientific literature supports the safety of EO mouthrinses,(7-9) including use in xerostomic patients,(8) and evidence [...]

Oral Cancer Foundation News Team - A2011-09-02T19:11:29-07:00September, 2011|Oral Cancer News|

Medicated patch shows promise in oral cancer prevention

Source: www.healthnewsdigest.com Author: press release Researchers at The Ohio State University Comprehensive Cancer Center have developed a medicated oral patch that allows a chemoprevention drug to release directly into precancerous lesions in the mouth over an extended time. The study evaluated the drug fenretinide, a synthetic derivative of vitamin A that has highly promising anti-cancer properties. Until now, scientists have failed to achieve a therapeutic, systemic dose of fenretinide because of drug toxicity and rapid release from the body. By using a new mucoadhesive patch invented by a team from Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and the University of Michigan, the researchers developed a delivery system that can provide continuous drug therapy to saliva-coated oral tissue. “The challenge with oral gels or rinses is the medication can dissolve in saliva before it penetrates into the tissue. This patch allows us to target and control drug delivery and tissue exposure,” says Dr. Susan Mallery, an oral pathologist at Ohio State’s Comprehensive Cancer Center. The patch consists of three layers: a disk saturated with fenretinide and polymers to make the drug more soluble in saliva, an adhesive ring to hold the disk in place, and a backing layer to ensure the medication stays within the patch. In their study recently published online by the journal Pharmaceutical Research, Mallery and co-investigator, Dr. Peter Larsen of Ohio State, tested the fenretinide patch using simulated saliva as well as lab animals. In [...]

Oral Cancer Foundation News Team - A2011-09-02T19:03:27-07:00September, 2011|Oral Cancer News|

Democrat Shelly Leonard, Former House District Candidate, Fights Cancer Again

Source: TampaBay By: Mike Brassfield, Times Staff Writer CLEARWATER — When she ran against incumbent state Rep. Ed Hooper last year, Shelly Leonard wasn't your typical candidate. She was a 37-year-old single mother — and a survivor of oral cancer. The feisty Democrat made her cancer history a part of her stump speech, talking about the need to make health insurance accessible to more people. "My tongue is scarred," she would say on the campaign trail, "but I have a strong voice." More than 16,000 people voted for her in Clearwater-based House District 50. But nearly 24,000 voted to keep Republican Hooper in office, so Leonard went back to her job as a social worker. Now she's facing some bad news. Leonard's oral cancer has returned. She's scheduled to undergo major surgery today at Moffitt Cancer Center in Tampa. "She's having surgery to remove four malignant tumors," said her friend and campaign treasurer, Van Farber. "After they remove the tumors, there's a question of how much of her tongue will be left after surgery — will she be able to talk in her normal voice, or just a whisper?" As tough as that is, it's actually an improvement over what her prognosis had been. As recently as six weeks ago, Leonard was told that her tumors were so large, she could lose part of her chin and some of her teeth and would need significant reconstructive surgery. "The most positive thing is, her tumors have shrunk since then," Farber said. [...]

Charlotte Parker2011-09-02T10:43:31-07:00September, 2011|Oral Cancer News|

New Research Proves Cancer-Fighting Virus can Kill Tumor Cells Without Harming Healthy Tissue

LOS ANGELES (Reuters) - Researchers have shown for the first time that a single intravenous infusion of a genetically engineered virus can home in on cancer, killing tumor cells in patients without harming healthy tissue. Scientists have been intrigued for decades with the idea of using viruses to alert the immune system to seek and destroy cancerous cells. That interest has taken off in recent years as advances in genetic engineering allow them to customize viruses that target tumors. The field received a boost in January when biotech giant Amgen Inc agreed to pay up to $1 billion for BioVex, the developer of experimental cancer-fighting virus OncoVex. But the only "oncolytic virus" so far approved by a regulatory agency is for treatment of head and neck cancer in China. In a study published in the journal Nature on Wednesday, scientists at institutions including the University of Ottawa and privately held biotech company Jennerex Inc said a small, early-stage trial of experimental viral therapy JX-954 found that it consistently infected tumors with only minimal and temporary side effects. The experimental virus will next be tested in a mid-stage trial of patients with liver cancer. "With chemotherapy you get drastic side effects," said Dr. John Bell, chief scientific officer at Jennerex and senior scientist at the Ottawa Hospital Research Institute. "Patients on this treatment only had 24-hour flu symptoms, and nothing after that." The trial, which involved 23 patients with various types of advanced cancer, was designed to assess the safety of [...]

Oral Cancer Foundation News Team - A2011-09-01T10:59:03-07:00September, 2011|Oral Cancer News|

Ear, nose and throat docs weigh in on controversial test

Source: commonhealth.wbur.org Author: Rachel Zimmerman Last week, WBUR’s Martha Bebinger wrote a story about doctors at Beth Israel Deaconess Medical Center who, for the first time, got access to a list of prices for common tests and procedures. The piece triggered a minor uprising among some ENT specialists, who offered impassioned comments on the story. Martha explains the controversy: One primary care doctor, David Ives, the medical director of Affiliated Physicians Group, the largest group of private doctors that admits patients to Beth Israel, reacted to the price of a nasal endoscopy and said he thinks the procedure is used too often when a physical exam would suffice. This comment angered many Ear, Nose and Throat specialists who say the development and use of this scope is one of the most important diagnostic tools in their field in recent history. Before filing the story, I searched for medical literature comparing either the cost effectiveness or the outcomes of a nasal endoscopy vs. a physical exam. I didn’t find anything. I did not call a representative of the American Academy of Otolaryngology for their views on nasal endoscopy. We offer that now. Wendy Stern is the chair elect of the Public Relations committee for the American Academy of Otolaryngology/Head and Neck Surgery, a former president of the Massachusetts Society of Otolaryngology. Dr. Stern says nasal endoscopy allows the physician to look for signs of bacterial infection, structural changes, polyps or tumors that would not be visible without this tool. Not using [...]

Oral Cancer Foundation News Team - A2011-08-30T22:01:28-07:00August, 2011|Oral Cancer News|

Blood filter to be tested on cancer patients

Source: www.signonsandiego.com Author: Keith Darcé A Santa Monica research center will test an experimental therapeutic filtering device being developed by Aethlon Medical on blood taken from cancer patients, the San Diego company said Wednesday. The study will target exosomes, bubbles of protein and RNA molecules excreted by cancerous cells that can block immune system cells from fighting the illness. By removing exosomes from circulating blood, Aethlon officials hope their device will improve the body's ability to fight cancer and the effectiveness of treatments such as chemotherapy. Blood taken from 25 patients with non-small cell lung cancer, prostate cancer, melanoma, sarcoma, and head and neck cancer will be circulated through the Hemopurifier device. In clinical use, blood would be filltered directly from the patient and returned to the body in a similar way to kidney dialysis. However, in the newly announced pre-clinical trial blood will not be returned to patients, Aethlon Chairman and Chief Executive Officer James Joyce said. "if we validate that our Hemopurifier is efficient in capturing exosomes, its possible that we could transition towards a human treatment study to evaluate exosome clearance from the entire circulatory system," he said. The test will be conducted by the Sarcoma Oncology Center, a nonprofit independent research institute focused on cancer therapy development. "This clinical histological study is a critical validation step in Aethlon's Hemopurifier strategy for cancer," said Dr. Sant Chawla, the trial's chief investigator. "The concept of 'subtractive therapy', eliminating a major mechanism of tumor progression and resistance to drugs, [...]

Oral Cancer Foundation News Team - A2011-08-27T18:04:11-07:00August, 2011|Oral Cancer News|

Students can’t commit to quitting

Source: www.gcsunade.com Author: Lindsay Peterson A Georgia College student steps outside, pauses and inhales, filling his lungs with acetone, ammonia, arsenic, benzene, butane, formaldehyde, lead and turpentine – just 8 of the more than 50 carcinogens found in the average cigarette. According to the Centers for Disease Control and Prevention, of the 46 million smokers in the U.S., college students are among the highest percentage of smokers. Almost 22 percent of adults ages 18-24 smoke, according to 2009 CDC data. Their professors are not far behind them in their smoking addiction. According to the CDC data, almost 22 percent of people ages 45-64 are smokers. In 2009, the CDC found that adults in the Southeast were among the most prevalent smokers in the United States. While there are no hard statistics for the percentage of students and staff that smoke at GC, it is not uncommon to see a familiar gathering of smokers sitting outside any of the dorms. Lauren Luker, junior mass communication major, started smoking in order to get a break at her job as a server. “You couldn’t have a break unless it was a smoke break,” Luker said. Now, eight years later, Luker is worried about the health of her lungs and is planning on quitting after several previous failed attempts. However, quitting such an addictive habit is not always easy, as Luker knows. According to the National Institute on Drug Abuse, nicotine is as addictive as heroin and cocaine. Fortunately for GC students and staff [...]

Oral Cancer Foundation News Team - A2011-08-27T18:04:50-07:00August, 2011|Oral Cancer News|